Clearside Biomed Stock Price, News & Analysis

Clearside Biomedical (NASDAQ: CLSD), a biopharmaceutical company focused on delivering therapies to the back of the eye through the suprachoroidal space (SCS®), will participate in the Stifel 2025 Virtual Ophthalmology Forum. The company's management will engage in a fireside chat on Tuesday, May 27, 2025, at 9:00 a.m. ET. Investors and interested parties can access the live and archived webcast through the Events and Presentations section of Clearside's website. The webcast recording will remain available for three months after the event.

Clearside Biomedical (NASDAQ: CLSD) reported Q1 2025 financial results and corporate updates. Key highlights include a successful End-of-Phase 2 FDA meeting for CLS-AX in wet AMD, targeting a flexible three-to-six-month dosing label. Q1 revenue was $2.3 million, up from $0.2M in Q1 2024, driven by partner milestone payments. Net loss decreased to $8.2 million ($0.11/share) from $11.8M ($0.17/share) year-over-year. The company's cash position stands at $13.6 million, expected to fund operations into Q4 2025. Notable partner progress includes ARCATUS® approvals in Australia and Singapore, and an NDA under review in China. BioCryst Pharmaceuticals received authorization to start clinical trials for avoralstat in Australia using Clearside's SCS Microinjector®.

Clearside Biomedical (NASDAQ: CLSD) showcased six presentations at the ARVO 2025 Meeting, highlighting their CLS-AX (axitinib injectable suspension) program and suprachoroidal drug delivery platform. The Phase 2b ODYSSEY trial for CLS-AX demonstrated positive results in treating wet AMD, maintaining stable vision while reducing injection frequency. Key developments include:

• Development of the first machine learning algorithm for imaging suprachoroidal space (SCS) drug delivery
• Creation of a novel force analysis method for drug-device optimization
• Over 15,000 completed injections in their clinically validated training program
• Successful Phase 2b results supporting CLS-AX as a potential safe and long-acting therapy

The company's SCS Microinjector® technology positions Clearside as a leader in suprachoroidal drug delivery, offering a transformative approach to treating retinal diseases.

Clearside Biomedical (NASDAQ: CLSD), a biopharmaceutical company focused on delivering therapies to the back of the eye through the suprachoroidal space (SCS®), has scheduled the release of its first quarter 2025 financial results for Wednesday, May 14, 2025, after market close. The company has noted that it will not hold a conference call this quarter. Investors can access quarterly results and other investor-related information through the Investors section of Clearside's website.

Clearside Biomedical (NASDAQ: CLSD), a biopharmaceutical company focused on delivering therapies to the back of the eye through the suprachoroidal space (SCS®), will participate in the Citizens Life Sciences Conference. The company's management will engage in a fireside chat on May 7, 2025, at 1:00 p.m. ET. Investors can access the live and archived webcast through Clearside's website under the Investors section: Events and Presentations. The webcast recording will remain available for three months after the event.

Clearside Biomedical (Nasdaq: CLSD), a biopharmaceutical company focused on delivering therapies to the back of the eye through the suprachoroidal space (SCS®), has announced its participation in the 24th Annual Needham Virtual Healthcare Conference.

The company's leadership, including George Lasezkay, President and CEO, and Victor Chong, Chief Medical Officer and EVP of Research & Development, will engage in a fireside chat on Monday, April 7, 2025, at 12:45 p.m. ET. The presentation will be accessible via webcast through Clearside's website under the Investors section, with the recording remaining available for three months.

Clearside Biomedical (NASDAQ: CLSD) has announced its Q4 and full-year 2024 financial results. The company achieved a successful End-of-Phase 2 meeting with FDA for CLS-AX in wet AMD, aligning on Phase 3 plans. Their Asia-Pacific partner received regulatory acceptance for ARCATUS® in China for uveitic macular edema treatment.

Financial highlights for Q4 2024: Revenue was $0.3 million (down from $6.3M in Q4 2023), net loss increased to $7.3 million ($0.10 per share). Full-year 2024 results showed revenue of $1.7 million (down from $8.2M in 2023) and net loss of $34.4 million ($0.47 per share). Cash position stands at $20.0 million, sufficient to fund operations into Q4 2025.

The company's partners are advancing various clinical programs: REGENXBIO/AbbVie planning Phase 3 for sura-vec, Aura Biosciences enrolling for Phase 3 CoMpass trial, and BioCryst preparing to initiate clinical testing of avoralstat in 2025.

Clearside Biomedical (Nasdaq: CLSD) announced six abstracts accepted for presentation at the Association for Research in Vision and Ophthalmology (ARVO) 2025 Meeting, scheduled for May 4-8, 2025 in Salt Lake City. The presentations focus on the company's suprachoroidal drug delivery platform and its SCS Microinjector®.

The abstracts cover various aspects including top-line results from the ODYSSEY Phase 2b study of CLS-AX in neovascular age-related macular degeneration (nAMD), preclinical and clinical corroboration of CLS-AX's therapeutic potential, a decade-long literature review of suprachoroidal drug delivery, validation of injection training programs, suspension formulation analysis, and a novel deep learning algorithm for suprachoroidal space measurement.

According to Dr. Victor Chong, Chief Medical Officer, their proprietary formulation of axitinib (CLS-AX) shows promise as a durable, potent pan-VEGF inhibitor for wet AMD treatment, positioning suprachoroidal drug delivery as a mainstream option for retinal care.

Clearside Biomedical (NASDAQ: CLSD) presented updates on its lead clinical program CLS-AX and suprachoroidal delivery platform at the 2025 Wet AMD & Diabetic Eye Disease Summit. The company showcased post-hoc analyses comparing rescue criteria and intervention-free rates for Tyrosine Kinase Inhibitors (TKIs) in wet AMD development.

Chief Medical Officer Victor Chong highlighted the potential benefits of their SCS Microinjector® technology, which delivers therapies directly to the retina, macula, and choroid. The presentation emphasized CLS-AX's advantages in treating wet AMD, including pan-VEGF receptors blockage and extended drug delivery. The suprachoroidal approach shows potential safety benefits, including minimal risk of endophthalmitis and cataract.

Following a successful End-of-Phase 2 meeting with the FDA, Clearside outlined Phase 3 trial plans targeting the $12+ billion wet AMD market. The company's strategy aligns with FDA's 2023 draft guidance, focusing on reducing treatment burden while maintaining visual acuity alongside anti-VEGF biologics flexibility.